These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 21197148)

  • 21. Formulary management of 2 new agents: lorcaserin and phentermine/topiramate for weight loss.
    Kelly EM; Tungol AA; Wesolowicz LA
    J Manag Care Pharm; 2013 Oct; 19(8):642-54. PubMed ID: 24074010
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical pharmacotherapy for obesity: current drugs and those in advanced development.
    Halford JC
    Curr Drug Targets; 2004 Oct; 5(7):637-46. PubMed ID: 15473253
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-Obesity Drugs: Long-Term Efficacy and Safety: An Updated Review.
    Tak YJ; Lee SY
    World J Mens Health; 2021 Apr; 39(2):208-221. PubMed ID: 32202085
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term effects of weight-reducing drugs in hypertensive patients.
    Siebenhofer A; Jeitler K; Horvath K; Berghold A; Siering U; Semlitsch T
    Cochrane Database Syst Rev; 2013 Mar; (3):CD007654. PubMed ID: 23543553
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Recent progress and novel perspectives on obesity pharmacotherapy].
    Faria AM; Mancini MC; Melo ME; Cercato C; Halpern A
    Arq Bras Endocrinol Metabol; 2010 Aug; 54(6):516-29. PubMed ID: 20857056
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacological management of obesity in pediatric patients.
    Boland CL; Harris JB; Harris KB
    Ann Pharmacother; 2015 Feb; 49(2):220-32. PubMed ID: 25366340
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacotherapy in obesity: a systematic review and meta-analysis of randomized controlled trials of anti-obesity drugs.
    Singh AK; Singh R
    Expert Rev Clin Pharmacol; 2020 Jan; 13(1):53-64. PubMed ID: 31770497
    [No Abstract]   [Full Text] [Related]  

  • 28. Drug safety evaluation of naltrexone/bupropion for the treatment of obesity.
    Verpeut JL; Bello NT
    Expert Opin Drug Saf; 2014 Jun; 13(6):831-41. PubMed ID: 24766397
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacotherapy of obesity - state of the art.
    Matyjaszek-Matuszek B; Szafraniec A; Porada D
    Endokrynol Pol; 2018; 69(4):. PubMed ID: 30209803
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacotherapy for the management of obesity.
    Patel D
    Metabolism; 2015 Nov; 64(11):1376-85. PubMed ID: 26342499
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New obesity agents: lorcaserin and phentermine/topiramate.
    Fleming JW; McClendon KS; Riche DM
    Ann Pharmacother; 2013; 47(7-8):1007-16. PubMed ID: 23800750
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current pharmacotherapies for obesity: A practical perspective.
    Golden A
    J Am Assoc Nurse Pract; 2017 Oct; 29(S1):S43-S52. PubMed ID: 29024552
    [TBL] [Abstract][Full Text] [Related]  

  • 33. AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity.
    Grunvald E; Shah R; Hernaez R; Chandar AK; Pickett-Blakely O; Teigen LM; Harindhanavudhi T; Sultan S; Singh S; Davitkov P;
    Gastroenterology; 2022 Nov; 163(5):1198-1225. PubMed ID: 36273831
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety assessment of combination therapies in the treatment of obesity: focus on naltrexone/bupropion extended release and phentermine-topiramate extended release.
    Halpern B; Mancini MC
    Expert Opin Drug Saf; 2017 Jan; 16(1):27-39. PubMed ID: 27732121
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Obesity Pharmacotherapy.
    Saunders KH; Umashanker D; Igel LI; Kumar RB; Aronne LJ
    Med Clin North Am; 2018 Jan; 102(1):135-148. PubMed ID: 29156182
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term pharmacotherapy for obesity and overweight.
    Padwal R; Li SK; Lau DC
    Cochrane Database Syst Rev; 2004; 2003(3):CD004094. PubMed ID: 15266516
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term pharmacotherapy for obesity and overweight.
    Padwal R; Li SK; Lau DC
    Cochrane Database Syst Rev; 2003; (4):CD004094. PubMed ID: 14584004
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Management of obesity and cardiometabolic risk - role of phentermine/extended release topiramate.
    Sweeting AN; Tabet E; Caterson ID; Markovic TP
    Diabetes Metab Syndr Obes; 2014; 7():35-44. PubMed ID: 24550678
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of Weight-Loss Medications on Cardiometabolic Risk Profiles: A Systematic Review and Network Meta-analysis.
    Khera R; Pandey A; Chandar AK; Murad MH; Prokop LJ; Neeland IJ; Berry JD; Camilleri M; Singh S
    Gastroenterology; 2018 Apr; 154(5):1309-1319.e7. PubMed ID: 29305933
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rimonabant for the treatment of overweight and obese people.
    Burch J; McKenna C; Palmer S; Norman G; Glanville J; Sculpher M; Woolacott N
    Health Technol Assess; 2009 Oct; 13 Suppl 3():13-22. PubMed ID: 19846024
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.